全球哺乳動物細胞庫市場

預計到 2030 年全球哺乳動物細胞庫市場規模將達 11 億美元

全球哺乳動物細胞庫市場規模預計在2024年為4.826億美元，到2030年將達到11億美元，2024年至2030年的複合年成長率為14.0%。本報告分析的細分市場之一TEP技術，預計其複合年成長率為13.2%，到分析期結束時規模將達到6.218億美元。 IEP技術細分市場在分析期間內的複合年成長率預計為15.9%。

美國市場規模估計為 1.315 億美元，中國市場預計複合年成長率為 18.5%

美國細胞庫市場規模預計2024年達到1.315億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到2.249億美元，2024年至2030年的複合年成長率為18.5%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為10.4%和12.5%。在歐洲，預計德國的複合年成長率為11.1%。

全球哺乳動物細胞庫市場—主要趨勢與促進因素摘要

為什麼哺乳動物細胞庫是生物製藥開發與製造的基石？

哺乳動物細胞庫是生物製藥開發和商業生產的重要支柱，因為它可以保存和繁殖基因一致、無污染的細胞株。這些細胞庫是製造複雜生物製藥的基礎來源，包括單株抗體、重組蛋白、疫苗和基因療法。與微生物系統不同，哺乳動物細胞具有進行複雜的轉譯後修飾的獨特能力，這對許多生技藥品的治療效果和穩定性至關重要。隨著全球對生技藥品的需求持續成長，為了確保產品的一致性和安全性，特徵明確且穩定的細胞株的重要性呈指數級成長。主細胞庫 (MCB) 和工作細胞庫 (WCB) 均按照良好生產規範 (GMP) 精心創建，以確保大規模生產的可重複性，同時遵守嚴格的監管要求。正確的儲存、記錄和可追溯性是細胞庫業務的關鍵要素。隨著生物製藥產品線不斷擴展，療法標靶性和個人化程度不斷提升，哺乳動物細胞庫的作用也不斷擴展，以支持自體和異體細胞療法。建立強大的細胞庫的策略價值在於降低長期開發風險、簡化規模化生產流程，並快速回應監管審核和產品召回。這些能力凸顯了它們對於生技藥品從早期研究邁向全面商業化生產至關重要。

科技創新如何使細胞培養過程更有效率、更可靠？

生物加工技術、自動化和分析技術的進步顯著提高了哺乳動物細胞庫操作的精確度、擴充性和可靠性。冷凍保存技術的創新，例如控制冷凍速率和冷凍保護劑最佳化，提高了細胞活力和解凍後的遺傳穩定性，這對於長期維持主細胞庫和工作細胞庫的完整性至關重要。細胞培養、收穫和分裝過程的自動化提高了操作通量和一致性，同時降低了污染和人為錯誤的風險。現代生物庫設施擴大利用機器人技術和封閉式系統技術來支援無菌處理並最大限度地減少人工干預。此外，諸如次世代定序和即時PCR之類的高級分析技術正被用於徹底表徵細胞株，並確保它們不含不定孢子、黴漿菌和遺傳漂變。人工智慧和機器學習開始在生物庫的預測性維護和品質預測中發揮作用，使設施能夠監測趨勢並在產品完整性受到損害之前預防設備和活力問題。雲端基礎的資料管理平台正在被廣泛採用，以實現集中記錄、機構間即時協作，並支援具有完全可追溯性的監管審核。這些技術不僅簡化了營運，還增強了對FDA、EMA和ICH等監管機構制定的不斷發展的國際標準的合規性。因此，企業可以顯著縮短上市時間，同時保持高品質和可重複性的標準，這進一步凸顯了投資技術先進的哺乳動物細胞庫系統的戰略重要性。

哪些產業趨勢正在影響全球對哺乳動物細胞庫服務的需求？

各種行業趨勢正在推動全球對哺乳動物細胞庫服務的需求，尤其是在生技藥品和細胞療法成為現代醫學核心的背景下。單株抗體、生物相似藥和個人化藥物需求的激增，推動了大型生物製藥公司和受託製造廠商(CDMO) 對可擴展且可靠的細胞庫基礎設施的投資。細胞和基因治療產品線的快速擴張也推動了對客製化細胞庫解決方案的需求，這些解決方案能夠在嚴格的品管下支援自體和異體工作流程。此外，隨著生物製藥創新擴展到罕見疾病和孤兒病領域，越來越多的公司開始儲存規模較小、高度專業化的細胞株，這些細胞系必須符合嚴格的監管和安全基準。生技藥品生產的全球化正在推動區域細胞庫設施的建立，以支持分散的生產模式，提高供應鏈的彈性，並滿足當地的監管要求。同時，生物技術領域新興企業和學術研究機構的興起，正在推動提供承包細胞庫解決方案的第三方服務提供者的成長。這些服務不僅包括冷凍保存和存儲，還包括細胞株表徵、文件記錄和法規支援。向外包和合作模式的轉變使中小企業無需大量資本投入即可獲得高品質的基礎設施。隨著生物製藥行業日益數據主導，對將生物保存與數位監控、合規性追蹤和分析相結合的整合解決方案的需求日益成長。這些趨勢正在共同擴大全球哺乳動物細胞庫市場的範圍和規模。

哪些因素推動了全球哺乳動物細胞庫市場的成長？

全球哺乳動物細胞庫市場的成長受到與生物製藥擴張、法規遵循和技術進步相關的幾個關鍵因素的驅動。其中一個關鍵促進因素是越來越多的生物製藥進入臨床開發和商業化階段，尤其是需要哺乳動物系統來表現的複雜生技藥品。治療性蛋白質生產對中國倉鼠卵巢(CHO) 細胞和其他哺乳動物宿主的日益依賴，直接要求建立強大且合規的細胞庫系統。日益嚴格的生物安全、可追溯性和產品一致性監管要求，迫使生物製藥公司投資高品質的細胞庫設施和服務。此外，個人化醫療（尤其是在腫瘤學和再生醫學領域）的發展，催生了對患者特異性細胞株的需求，這些細胞系必須在嚴格控制的條件下儲存和管理。提供專業細胞庫服務的合約開發與生產組織 (CDMO) 的擴張，使企業能夠擴大業務規模並迅速進入全球市場。此外，生物製造領域不斷成長的政府資金和官民合作關係正在支持基礎設施建設，並鼓勵採用GMP級生物銀行方法。涉及幹細胞療法、免疫療法和CRISPR等基因編輯平台的臨床試驗的興起，也促進了對安全、可擴展的哺乳動物細胞庫的需求。冷凍保存、數位追蹤和細胞株鑑定技術的進步，正在強化內部和外包細胞庫解決方案的價值提案。綜合起來，這些因素使哺乳動物細胞庫成為未來生技藥品開發、製造和商業化的基礎要素。

部分

技術（TEP 技術、IEP 技術、SEP 技術）、用途（MCB 用途、WCB 用途、EoP 用途、研發 CB 用途）、最終用途（學術/研究機構最終用途、生物製藥公司最終用途、CRO 最終用途）

受訪公司範例

• 3P Biopharmaceuticals
• Advanced Therapies
• Becton, Dickinson and Company（BD）
• Charles River Laboratories
• Corning Incorporated
• Cryo-Cell International
• Danaher Corporation
• Eppendorf AG
• Eurofins DiscoverX/SwissBio
• Fujifilm Irvine Scientific
• GE Healthcare Life Sciences（Cytiva）
• InvivoGen
• Lonza Group Ltd
• Merck KGaA（MilliporeSigma）
• Sartorius AG
• Sigma-Aldrich Corporation
• SCTbio
• Takara Bio Inc.
• Thermo Fisher Scientific
• WuXi AppTec/WuXi Biologics
• Cedarlane Laboratories

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Mammalian Cell Banking Market to Reach US$1.1 Billion by 2030

The global market for Mammalian Cell Banking estimated at US$482.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. TEP Technology, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$621.8 Million by the end of the analysis period. Growth in the IEP Technology segment is estimated at 15.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$131.5 Million While China is Forecast to Grow at 18.5% CAGR

The Mammalian Cell Banking market in the U.S. is estimated at US$131.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$224.9 Million by the year 2030 trailing a CAGR of 18.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.4% and 12.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global Mammalian Cell Banking Market - Key Trends & Drivers Summarized

Why Is Mammalian Cell Banking a Cornerstone in Biopharmaceutical Development and Manufacturing?

Mammalian cell banking has become an essential pillar in the development and commercial production of biopharmaceuticals due to its role in preserving and reproducing genetically consistent and contamination-free cell lines. These cell banks serve as the foundational source for producing complex biological products such as monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. Unlike microbial systems, mammalian cells are uniquely capable of performing intricate post-translational modifications, which are critical for the therapeutic efficacy and stability of many biologics. As the global demand for biologics continues to rise, the importance of well-characterized and stable cell lines that ensure product consistency and safety has grown exponentially. Master cell banks (MCBs) and working cell banks (WCBs) are meticulously created under Good Manufacturing Practices (GMP) to guarantee reproducibility in large-scale production while complying with stringent regulatory requirements. Proper storage, documentation, and traceability are critical components of cell banking operations, as any variation can lead to costly delays, failed batches, or compromised patient safety. As biopharma pipelines expand with more targeted and personalized therapies, the role of mammalian cell banking is also broadening to include support for autologous and allogeneic cell therapies. The strategic value of establishing robust cell banks lies in reducing long-term development risks, streamlining scale-up, and enabling faster response to regulatory audits and product recalls. These capabilities highlight why mammalian cell banking is indispensable for both early-stage research and full-scale commercial production across the biologics landscape.

How Are Technological Innovations Enhancing the Efficiency and Reliability of Cell Banking Processes?

Advancements in bioprocessing technologies, automation, and analytics are significantly enhancing the precision, scalability, and reliability of mammalian cell banking operations. Innovations in cryopreservation techniques, such as controlled-rate freezing and cryoprotectant optimization, are improving cell viability and genetic stability post-thaw, which is critical for preserving the integrity of both master and working cell banks over time. Automation in cell culture, harvesting, and aliquoting processes reduces the risk of contamination and human error while boosting operational throughput and consistency. Modern biobanking facilities are increasingly utilizing robotics and closed-system technologies to support sterile processing and minimize manual interventions. In addition, advanced analytics such as next-generation sequencing and real-time PCR are being applied to thoroughly characterize cell lines, ensuring they are free from adventitious agents, mycoplasma, and genetic drift. Artificial intelligence and machine learning are beginning to play a role in predictive maintenance and quality forecasting for biobanks, allowing facilities to monitor trends and preempt equipment or viability issues before they compromise product integrity. Cloud-based data management platforms are being adopted to centralize records, enable real-time collaboration across sites, and support regulatory audits with full traceability. These technologies not only streamline operations but also enhance compliance with evolving international standards from regulatory bodies such as the FDA, EMA, and ICH. As a result, companies can significantly reduce time to market while maintaining high standards of quality and reproducibility, thereby reinforcing the strategic importance of investing in technologically advanced mammalian cell banking systems.

What Industry Trends Are Shaping the Demand for Mammalian Cell Banking Services Globally?

A variety of industry trends are contributing to increased demand for mammalian cell banking services across the globe, especially as biologics and cell-based therapies become central to modern medicine. The surge in demand for monoclonal antibodies, biosimilars, and personalized medicines is prompting both large biopharmaceutical firms and contract development and manufacturing organizations (CDMOs) to invest in scalable and reliable cell banking infrastructure. The rapid expansion of cell and gene therapy pipelines is also driving a need for customized cell banking solutions that can support autologous and allogeneic workflows under rigorous quality controls. Additionally, as biopharmaceutical innovation expands into rare diseases and orphan drugs, companies are increasingly banking smaller, highly specialized cell lines that must meet strict regulatory and safety benchmarks. The globalization of biologics manufacturing is leading to the establishment of regional cell banking facilities to support decentralized production models, improve supply chain resilience, and meet local regulatory requirements. Meanwhile, the rise of start-ups and academic research institutions in the biotech space is fueling the growth of third-party service providers offering turnkey cell banking solutions. These services include not only cryopreservation and storage but also cell line characterization, documentation, and regulatory support. The shift toward outsourcing and partnership models is enabling smaller players to access high-quality infrastructure without large capital investments. As the biopharma industry becomes more data-driven, demand is growing for integrated solutions that combine biological storage with digital monitoring, compliance tracking, and analytics. Together, these trends are expanding the scope and scale of the global mammalian cell banking market.

What Factors Are Driving Growth in the Global Mammalian Cell Banking Market?

The growth in the global mammalian cell banking market is driven by several critical factors related to biopharmaceutical expansion, regulatory compliance, and technological progress. One of the primary drivers is the rising number of biopharmaceutical products entering clinical development and commercialization, especially complex biologics that require mammalian systems for expression. The increasing reliance on Chinese Hamster Ovary (CHO) cells and other mammalian hosts for producing therapeutic proteins is directly tied to the need for robust and compliant cell banking systems. Regulatory expectations around biosafety, traceability, and product consistency are becoming more stringent, compelling biopharma companies to invest in high-quality cell banking facilities and services. Additionally, the growth of personalized medicine, particularly in oncology and regenerative medicine, is creating demand for patient-specific cell lines that must be stored and managed under carefully controlled conditions. Expansion of CDMOs offering specialized cell banking services is making it easier for companies to scale operations and enter global markets more quickly. Furthermore, increased government funding and public-private partnerships in biomanufacturing are supporting infrastructure development and encouraging adoption of GMP-grade biobanking practices. The rise in clinical trials involving stem cell therapies, immunotherapies, and gene editing platforms such as CRISPR is also contributing to the need for secure and scalable mammalian cell storage. Technological advances in cryopreservation, digital tracking, and cell line authentication are enhancing the value proposition for both in-house and outsourced cell banking solutions. Collectively, these factors are positioning mammalian cell banking as a foundational element in the future of biologics development, manufacturing, and commercialization.

SCOPE OF STUDY:

The report analyzes the Mammalian Cell Banking market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (TEP Technology, IEP Technology, SEP Technology); Application (MCB Application, WCB Application, EoP Application, R&D CB Application); End-Use (Academic & Research Institute End-Use, Biopharma Companies End-Use, CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• 3P Biopharmaceuticals
• Advanced Therapies
• Becton, Dickinson and Company (BD)
• Charles River Laboratories
• Corning Incorporated
• Cryo-Cell International
• Danaher Corporation
• Eppendorf AG
• Eurofins DiscoverX / SwissBio
• Fujifilm Irvine Scientific
• GE Healthcare Life Sciences (Cytiva)
• InvivoGen
• Lonza Group Ltd
• Merck KGaA (MilliporeSigma)
• Sartorius AG
• Sigma-Aldrich Corporation
• SCTbio
• Takara Bio Inc.
• Thermo Fisher Scientific
• WuXi AppTec / WuXi Biologics
• Cedarlane Laboratories

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Mammalian Cell Banking - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rapid Expansion of Biologics and Cell-Based Therapies Throws the Spotlight on Mammalian Cell Banking as a Foundational Bioprocessing Asset
  • Growth in Monoclonal Antibody and Vaccine Production Propels Demand for Master and Working Cell Banks with High Viability and Stability
  • Here's the Story: Regulatory Requirements from FDA and EMA Strengthen the Business Case for GMP-Compliant Cell Banking Protocols
  • Increased R&D in Cell and Gene Therapy Drives the Need for Customized, High-Fidelity Mammalian Cell Line Repositories
  • Here's How Cryopreservation Technology Advancements Are Enhancing Long-Term Storage and Post-Thaw Recovery Rates
  • Rising Outsourcing to CDMOs and CROs Spurs Demand for Scalable and Secure Cell Banking Infrastructure
  • Growth of Biosimilars and Personalized Medicine Expands the Use of Mammalian Cell Banks Across Smaller, Targeted Production Runs
  • Here's How Automation and Robotics Are Improving Consistency, Traceability, and Contamination Control in Cell Banking Workflows
  • Surge in Biomanufacturing Activity in Emerging Markets Accelerates Establishment of Regional Cell Banking Facilities
  • Here's How Advances in Cell Line Engineering Are Elevating the Importance of Cell Bank Characterization and Genetic Stability
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mammalian Cell Banking Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mammalian Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for TEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for TEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for TEP Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for IEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for IEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for IEP Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for SEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for SEP Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for SEP Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Academic & Research Institute End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Academic & Research Institute End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Academic & Research Institute End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for MCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for MCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for MCB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for WCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for WCB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for WCB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for EoP Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for EoP Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for EoP Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for R&D CB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for R&D CB Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for R&D CB Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• JAPAN
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• CHINA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• EUROPE
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Mammalian Cell Banking by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• FRANCE
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• GERMANY
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Mammalian Cell Banking by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• INDIA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Mammalian Cell Banking by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Mammalian Cell Banking by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Mammalian Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030
• AFRICA
  • Mammalian Cell Banking Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Mammalian Cell Banking by Technology - TEP Technology, IEP Technology and SEP Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Mammalian Cell Banking by Technology - Percentage Breakdown of Value Sales for TEP Technology, IEP Technology and SEP Technology for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Mammalian Cell Banking by End-Use - CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Mammalian Cell Banking by End-Use - Percentage Breakdown of Value Sales for CROs End-Use, Academic & Research Institute End-Use and Biopharma Companies End-Use for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Mammalian Cell Banking by Application - MCB Application, WCB Application, EoP Application and R&D CB Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Mammalian Cell Banking by Application - Percentage Breakdown of Value Sales for MCB Application, WCB Application, EoP Application and R&D CB Application for the Years 2014, 2025 & 2030

IV. COMPETITION